Form 4: Labcorp EVP Caveney nets 6,385 shares via vesting

Labcorp executive Brian J. Caveney received 11,290 shares from vested performance awards and withheld 4,905 shares for taxes, ending with 36,491.9234 shares owned directly.

Summary

• Brian J. Caveney (EVP, Pres of ED, CMO & CSO) reported equity transactions on March 26, 2026 for Labcorp Holdings Inc. (LH).
• Acquired 9,304 and 1,986 common shares at $0 from performance awards tied to the three-year period ended December 31, 2025.
• Withheld 4,042 and 863 shares at $268.38 per share to satisfy tax obligations.
• Direct beneficial ownership after transactions: 36,491.9234 shares.
• Net increase in direct holdings: 6,385 shares.
• Activity reflects routine vesting of long-term performance awards and associated tax withholding; no open-market purchases or sales reported.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as neutral: routine PSU vesting increased insider ownership, but activity was compensation-driven with no discretionary open-market buys.

Positives

• Net increase of 6,385 shares in insider’s direct ownership, suggesting alignment with shareholders.
• Performance awards vested for a completed three-year period ended December 31, 2025, indicating milestone completion.
• No open-market sales beyond tax withholding, limiting potential negative signaling.

Negatives

• 4,905 shares withheld for taxes at $268.38 reduced the gross shares added.
• No discretionary open-market buying, which can sometimes provide a stronger positive signal.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4.

Management Comments

• Shares acquired on March 26, 2026, pursuant to a performance award granted on February 7, 2023, relating to performance during the three-year period ended December 31, 2025.
• Stock withholding to satisfy tax withholding obligations.
• Shares acquired on March 26, 2026, pursuant to a performance award granted on May 5, 2023, relating to performance during the three-year period ended December 31, 2025.

Industry Context

StockSavvy.ai notes that vesting of three-year performance-based equity with net share settlement for taxes is standard across diagnostics and broader healthcare peers and typically carries neutral signaling absent open-market purchases or sales.

Comparison to Industry Standards

• Three-year performance share vesting with net share settlement mirrors practices at Quest Diagnostics (DGX), Becton Dickinson (BDX), and HCA Healthcare (HCA).
• Absence of open-market buying contrasts with stronger insider conviction signals sometimes seen when executives purchase shares outright (e.g., periodic DGX insider buys).
• Use of contemporaneous market price for tax withholding is conventional across S&P 500 issuers.

Related Party Transactions

• Routine equity compensation to an executive officer with share withholding to satisfy taxes, reported under Section 16.

Stakeholder Impact

• Shareholders: modestly positive optics from higher insider ownership, though changes stem from routine vesting.
• Employees: reflects operation of the company’s long-term incentive plan based on a completed three-year performance period.
• Creditors: no impact disclosed.

Next Steps

• No additional actions or milestones disclosed.

Key Dates

Recommendation

Activity reflects standard vesting and tax withholding without incremental strategic or financial information; maintain a neutral stance pending fundamental updates.

Keywords

Labcorp, LH, Form 4, insider transaction, performance stock units, executive compensation, stock withholding, beneficial ownership, healthcare diagnostics